Given the observed positive role of SHP2 in promoting melanoma cell viability, motility, anchorage-independent growth, as well as ERK1/2 and PI3K/AKT pathway activation, we speculated that pharmacological inhibition of SHP2 could counteract these positive effects thereby benefit melanoma treatment. This evidence concerns the gene PTPN11 and melanoma.